New drug aims to halt early blood cancer before it starts

NCT ID NCT03236428

First seen Mar 29, 2026 · Last updated Apr 24, 2026 · Updated 5 times

Summary

This study tests a drug called daratumumab in people with two early blood conditions that can lead to multiple myeloma. The goal is to see if the drug can reduce or control the abnormal cells, preventing progression to active cancer. Participants receive treatment for up to 20 cycles, and researchers track how well the disease responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Karmanos Cancer Insitute

    Detroit, Michigan, 48201, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02214, United States

  • Pacific Cancer Care

    Monterey, California, 93940, United States

Conditions

Explore the condition pages connected to this study.